Nina Norin-Greilert
Danderyd, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Vaccination-first immune priming shapes a sustained mRNA vaccine-induced IgG4 class switch that associates with SARS-CoV-2 breakthrough infection risk.
Journal: Scientific reports
Published: May 29, 2026
Logistics for Rapid Isolation of Viruses From Humans.
Journal: Health security
Published: October 22, 2024
Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum.
Journal: Frontiers in immunology
Published: November 29, 2023
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.
Journal: The Lancet. Infectious diseases
Published: November 24, 2023
Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.
Journal: The New England journal of medicine
Published: October 27, 2023
Point prevalence of SARS-CoV-2 infection among healthcare workers in March and June 2023 in Sweden.
Journal: The Lancet regional health. Europe
Published: July 21, 2023
Mucosal IgA protects against BQ.1 and BQ.1.1 infection.
Journal: The Lancet. Infectious diseases
Published: June 08, 2023
7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection.
Journal: The Lancet. Infectious diseases
Published: October 28, 2022
Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.
Journal: The New England journal of medicine
Published: September 14, 2022
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
Journal: Vaccines
Published: February 02, 2022
Last Updated: 09/26/2026